Proxima
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $80.0Mattributed |
|---|---|
| Latest round | seed, $80.0M, 2026-01-13attributed |
| Founded | unknown |
| Headquarters | Cambridge |
| Industry | bio |
| Stage | series-b+ |
| Website | proxima.bio |
Proxima is an AI drug discovery company building medicines that modulate protein-to-protein interactions rather than toggling single proteins. It serves biopharma targeting diseases long considered undruggable. Its edge is pairing its NeoLink data engine with Neo AI models to discover proximity-modulating small molecules.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-01-13 | seed | $80.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $80.0M | attributed | news-misc named as publisher. No document URL on file. |
| Total raised $80.0M | attributed | news-misc named as publisher. No document URL on file. |
| Company existence | self-reported | proxima.bio, read 2026-05-07 |
| Description | self-reported | proxima.bio, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.